Free Trial
→ M.A.G.A. is Finished – This Could be even Better (From Paradigm Press) (Ad) Buy TRVI Stock  Free TRVI Stock Alerts

Trevi Therapeutics (TRVI) Financials

Trevi Therapeutics logo
$6.10 -0.10 (-1.61%)
As of 04:00 PM Eastern
Compare
Annual Income Statements for Trevi Therapeutics

Annual Income Statements for Trevi Therapeutics

This table shows Trevi Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Net Income / (Loss) Attributable to Common Shareholders		 -29 -29 -48
Consolidated Net Income / (Loss)		 -29 -29 -48
Net Income / (Loss) Continuing Operations		 -29 -29 -48
Total Pre-Tax Income 		-29 -29 -48
Total Operating Income		 -30 -34 -52
Total Gross Profit		 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00
Total Operating Expenses		 30 34 52
Selling, General & Admin Expense		 10 10 12
Research & Development Expense		 20 24 39
Total Other Income / (Expense), net		 0.72 4.83 3.58
Interest Expense		 1.16 0.39 0.00
Interest & Investment Income		 1.74 4.75 3.60
Other Income / (Expense), net		 0.14 0.47 -0.02
Income Tax Expense		 -0.04 -0.03 -0.03
Basic Earnings per Share		 ($0.45) ($0.29) ($0.47)
Weighted Average Basic Shares Outstanding		 64.54M 99.03M 101.97M
Diluted Earnings per Share		 ($0.45) ($0.29) ($0.47)
Weighted Average Diluted Shares Outstanding		 64.54M 99.03M 101.97M
Weighted Average Basic & Diluted Shares Outstanding		 60.05M 68.96M 96.68M

Quarterly Income Statements for Trevi Therapeutics

This table shows Trevi Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Income / (Loss) Attributable to Common Shareholders		 -8.27 -5.51 -6.40 -7.15 -7.67 -7.85 -11 -12 -13 -12
Consolidated Net Income / (Loss)		 -8.27 -5.51 -6.40 -7.15 -7.70 -7.82 -11 -12 -13 -11
Net Income / (Loss) Continuing Operations		 -8.27 -5.51 -6.40 -7.15 -7.70 -7.82 -11 -12 -13 -11
Total Pre-Tax Income 		-8.27 -5.53 -6.41 -7.18 -7.71 -7.80 -11 -12 -13 -11
Total Operating Income		 -8.41 -6.66 -7.56 -8.38 -9.05 -8.93 -12 -13 -14 -12
Total Operating Expenses		 8.41 6.66 7.56 8.38 9.05 8.93 12 13 14 12
Selling, General & Admin Expense		 2.64 2.34 2.56 2.54 2.72 2.42 3.10 3.27 2.86 2.91
Research & Development Expense		 5.77 4.32 5.00 5.84 6.32 6.52 8.80 10 11 9.33
Total Other Income / (Expense), net		 0.13 1.13 1.16 1.21 1.33 1.13 1.00 0.93 0.81 0.84
Interest Expense		 0.29 0.27 0.23 0.15 0.00 0.00 0.00 0.00 0.00 0.00
Interest & Investment Income		 0.42 1.12 1.22 1.21 1.18 1.14 1.00 0.94 0.83 0.84
Other Income / (Expense), net		 0.00 0.29 0.17 0.15 0.15 -0.00 -0.00 -0.01 -0.01 0.00
Income Tax Expense		 -0.01 -0.02 -0.01 -0.03 -0.01 0.02 -0.01 -0.01 -0.03 0.02
Basic Earnings per Share		 ($0.12) $0.05 ($0.06) ($0.07) ($0.08) ($0.08) ($0.11) ($0.12) ($0.13) ($0.11)
Weighted Average Basic Shares Outstanding		 68.90M 64.54M 98.61M 98.70M 99.33M 99.03M 99.52M 101.04M 101.28M 101.97M
Diluted Earnings per Share		 ($0.12) $0.05 ($0.06) ($0.07) ($0.08) ($0.08) ($0.11) ($0.12) ($0.13) ($0.11)
Weighted Average Diluted Shares Outstanding		 68.90M 64.54M 98.61M 98.70M 99.33M 99.03M 99.52M 101.04M 101.28M 101.97M
Weighted Average Basic & Diluted Shares Outstanding		 59.92M 60.05M 60.07M 63.85M 63.86M 68.96M 70.44M 72.59M 76.87M 96.68M

Annual Cash Flow Statements for Trevi Therapeutics

This table details how cash moves in and out of Trevi Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Net Change in Cash & Equivalents		 -24 20 1.70
Net Cash From Operating Activities		 -28 -32 -38
Net Cash From Continuing Operating Activities		 -28 -32 -38
Net Income / (Loss) Continuing Operations		 -29 -29 -48
Consolidated Net Income / (Loss)		 -29 -29 -48
Depreciation Expense		 0.04 0.12 0.15
Amortization Expense		 -0.31 -1.95 -1.37
Non-Cash Adjustments To Reconcile Net Income		 2.47 3.02 4.05
Changes in Operating Assets and Liabilities, net		 -1.23 -3.85 6.83
Net Cash From Investing Activities		 -107 59 -22
Net Cash From Continuing Investing Activities		 -107 59 -22
Purchase of Property, Plant & Equipment		 -0.16 -0.14 -0.04
Purchase of Investments		 -126 -9.93 -98
Sale and/or Maturity of Investments		 19 69 77
Net Cash From Financing Activities		 111 -7.91 61
Net Cash From Continuing Financing Activities		 111 -7.91 61
Repayment of Debt		 -5.85 -9.41 0.00
Repurchase of Common Equity		 -0.23 -0.26 0.00
Issuance of Common Equity		 105 0.07 0.07
Other Financing Activities, net		 12 1.69 61
Cash Interest Paid		 0.59 0.33 0.00

Quarterly Cash Flow Statements for Trevi Therapeutics

This table details how cash moves in and out of Trevi Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Change in Cash & Equivalents		 42 -54 -0.94 2.10 12 6.43 -19 -0.85 3.09 18
Net Cash From Operating Activities		 -8.58 -6.33 -8.20 -9.88 -7.28 -6.36 -10 -8.68 -9.56 -9.55
Net Cash From Continuing Operating Activities		 -8.58 -6.33 -8.20 -9.88 -7.28 -6.36 -10 -8.68 -9.56 -9.55
Net Income / (Loss) Continuing Operations		 -8.27 -5.51 -6.40 -7.15 -7.70 -7.82 -11 -12 -13 -11
Consolidated Net Income / (Loss)		 -8.27 -5.51 -6.40 -7.15 -7.70 -7.82 -11 -12 -13 -11
Depreciation Expense		 0.01 0.02 0.02 0.03 0.04 0.04 0.04 0.04 0.04 0.04
Amortization Expense		 -0.07 -0.46 -0.59 -0.39 -0.61 -0.35 -0.38 -0.34 -0.35 -0.30
Non-Cash Adjustments To Reconcile Net Income		 0.60 0.40 0.59 0.61 0.79 1.04 0.84 1.24 0.85 1.12
Changes in Operating Assets and Liabilities, net		 -0.85 -0.78 -1.81 -2.98 0.21 0.74 -0.06 2.73 3.15 1.01
Net Cash From Investing Activities		 -4.85 -48 8.96 20 18 13 -8.09 2.77 7.67 -24
Net Cash From Continuing Investing Activities		 -4.85 -48 8.96 20 18 13 -8.09 2.77 7.67 -24
Purchase of Property, Plant & Equipment		 -0.04 -0.12 -0.06 -0.04 -0.02 -0.02 0.00 -0.03 - -0.01
Purchase of Investments		 -6.81 -65 -8.98 - - -0.95 -30 -9.96 -13 -45
Sale and/or Maturity of Investments		 2.00 17 18 20 18 14 22 13 21 21
Net Cash From Financing Activities		 55 0.65 -1.70 -7.66 1.51 -0.05 -0.03 5.07 4.98 51
Net Cash From Continuing Financing Activities		 55 0.65 -1.70 -7.66 1.51 -0.05 -0.03 5.07 4.98 51
Issuance of Common Equity		 51 2.43 0.00 0.03 - 0.04 0.00 0.03 - 0.04
Other Financing Activities, net		 6.03 - 0.06 -0.02 1.68 -0.03 -0.03 5.03 4.98 51

Annual Balance Sheets for Trevi Therapeutics

This table presents Trevi Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Total Assets		 123 89 111
Total Current Assets		 123 88 109
Cash & Equivalents		 13 32 34
Short-Term Investments		 108 51 74
Prepaid Expenses		 0.80 3.62 0.94
Other Current Assets		 1.31 0.96 0.87
Plant, Property, & Equipment, net		 0.17 0.22 0.16
Total Noncurrent Assets		 0.23 1.64 1.32
Noncurrent Note & Lease Receivables		 0.00 0.21 0.16
Other Noncurrent Operating Assets		 0.23 1.43 1.16
Total Liabilities & Shareholders' Equity		 123 89 111
Total Liabilities		 16 6.86 11
Total Current Liabilities		 13 5.82 11
Short-Term Debt		 7.00 0.00 0.00
Accounts Payable		 2.86 1.81 3.41
Accrued Expenses		 3.52 3.71 6.81
Other Current Liabilities		 0.03 0.31 0.29
Total Noncurrent Liabilities		 2.16 1.03 0.75
Long-Term Debt		 2.15 0.00 0.00
Capital Lease Obligations		 0.00 1.00 0.75
Other Noncurrent Operating Liabilities		 0.00 0.03 0.00
Commitments & Contingencies		 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 107 83 100
Total Preferred & Common Equity		 107 83 100
Preferred Stock		 0.00 0.00 0.00
Total Common Equity		 107 83 100
Common Stock		 318 322 387
Retained Earnings		 -210 -239 -287
Accumulated Other Comprehensive Income / (Loss)		 -0.12 -0.03 0.06

Quarterly Balance Sheets for Trevi Therapeutics

This table presents Trevi Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Total Assets		 128 116 101 96 79 74 69
Total Current Assets		 127 114 99 94 77 72 67
Cash & Equivalents		 67 12 14 26 14 13 16
Short-Term Investments		 59 100 80 63 59 57 49
Prepaid Expenses		 1.29 1.33 2.98 4.04 3.23 1.80 1.18
Other Current Assets		 0.42 1.61 2.08 1.05 0.72 0.83 0.67
Plant, Property, & Equipment, net		 0.07 0.25 0.23 0.24 0.20 0.20 0.17
Total Noncurrent Assets		 0.92 1.76 1.54 1.71 1.59 1.48 1.40
Noncurrent Note & Lease Receivables		 - 0.24 0.23 0.22 0.19 0.18 0.17
Other Noncurrent Operating Assets		 0.92 1.52 1.31 1.49 1.40 1.30 1.23
Total Liabilities & Shareholders' Equity		 128 116 101 96 79 74 69
Total Liabilities		 18 14 5.90 6.29 6.23 7.64 9.94
Total Current Liabilities		 15 13 4.71 5.17 5.28 6.75 9.12
Short-Term Debt		 7.00 7.48 0.00 0.00 0.00 0.00 0.00
Accounts Payable		 2.33 1.98 1.35 1.26 2.11 1.51 1.61
Accrued Expenses		 5.25 3.47 3.08 3.63 2.84 4.93 7.21
Other Current Liabilities		 0.06 0.26 0.28 0.29 0.32 0.31 0.30
Total Noncurrent Liabilities		 3.82 1.27 1.19 1.11 0.95 0.88 0.82
Long-Term Debt		 3.80 0.00 0.00 0.00 0.00 0.00 0.00
Capital Lease Obligations		 - 1.15 1.10 1.05 0.95 0.88 0.82
Other Noncurrent Operating Liabilities		 0.02 0.12 0.09 0.06 0.00 0.00 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 110 102 95 90 72 66 59
Total Preferred & Common Equity		 110 102 95 90 72 66 59
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 110 102 95 90 72 66 59
Common Stock		 315 318 319 321 322 329 334
Retained Earnings		 -205 -216 -224 -231 -250 -262 -276
Accumulated Other Comprehensive Income / (Loss)		 -0.26 -0.09 -0.25 -0.22 -0.07 -0.08 0.14

Annual Metrics and Ratios for Trevi Therapeutics

This table displays calculated financial ratios and metrics derived from Trevi Therapeutics' official financial filings.

Metric 2022 2023 2024
Growth Metrics		 - - -
Revenue Growth		 0.00% 0.00% 0.00%
EBITDA Growth		 6.50% -17.47% -49.56%
EBIT Growth		 9.17% -12.39% -54.06%
NOPAT Growth		 7.91% -13.43% -51.89%
Net Income Growth		 14.11% 0.30% -64.84%
EPS Growth		 69.80% 35.56% -62.07%
Operating Cash Flow Growth		 2.66% -12.55% -20.64%
Free Cash Flow Firm Growth		 -5.57% -26.65% -0.13%
Invested Capital Growth		 25.70% 114.80% -1,353.21%
Revenue Q/Q Growth		 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 3.96% -7.43% -6.56%
EBIT Q/Q Growth		 5.86% -8.31% -6.85%
NOPAT Q/Q Growth		 5.13% -7.19% -6.86%
Net Income Q/Q Growth		 9.37% -8.66% -8.11%
EPS Q/Q Growth		 38.36% -81.25% -6.82%
Operating Cash Flow Q/Q Growth		 -0.36% -0.09% -9.10%
Free Cash Flow Firm Q/Q Growth		 -7.25% 2.17% -7.65%
Invested Capital Q/Q Growth		 20.45% -67.82% -26.68%
Profitability Metrics		 - - -
Gross Margin		 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00%
Tax Burden Percent		 99.88% 99.89% 99.94%
Interest Burden Percent		 98.06% 86.98% 93.02%
Effective Tax Rate		 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -46.82% -30.59% -52.59%
Cash Return on Invested Capital (CROIC)		 0.00% -4,891.01% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -46.82% -30.59% -52.59%
Return on Equity Simple (ROE_SIMPLE)		 -27.13% -35.21% -48.08%
Net Operating Profit after Tax (NOPAT)		 -21 -24 -36
NOPAT Margin		 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -12.29% -5.50% -12.54%
Return On Investment Capital (ROIC_SIMPLE)		 - -28.42% -35.93%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -30 -33 -52
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -30 -35 -53
Valuation Ratios		 - - -
Price to Book Value (P/BV)		 1.08 1.04 3.18
Price to Tangible Book Value (P/TBV)		 1.08 1.04 3.18
Price to Revenue (P/Rev)		 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 6.24 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00
Leverage & Solvency		 - - -
Debt to Equity		 0.09 0.01 0.01
Long-Term Debt to Equity		 0.02 0.01 0.01
Financial Leverage		 -1.07 -1.02 -1.04
Leverage Ratio		 1.30 1.12 1.10
Compound Leverage Factor		 1.27 0.97 1.02
Debt to Total Capital		 7.85% 1.20% 0.74%
Short-Term Debt to Total Capital		 6.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 1.85% 1.20% 0.74%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00%
Common Equity to Total Capital		 92.15% 98.80% 99.26%
Debt to EBITDA		 -0.30 -0.03 -0.01
Net Debt to EBITDA		 3.71 2.32 2.03
Long-Term Debt to EBITDA		 -0.07 -0.03 -0.01
Debt to NOPAT		 -0.44 -0.04 -0.02
Net Debt to NOPAT		 5.32 3.45 2.96
Long-Term Debt to NOPAT		 -0.10 -0.04 -0.02
Altman Z-Score		 2.34 3.61 12.79
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00%
Liquidity Ratios		 - - -
Current Ratio		 9.15 15.03 10.41
Quick Ratio		 8.99 14.25 10.24
Cash Flow Metrics		 - - -
Free Cash Flow to Firm (FCFF)		 -22 -28 -28
Operating Cash Flow to CapEx		 -17,720.13% -23,145.99% -109,302.86%
Free Cash Flow to Firm to Interest Expense		 -19.16 -72.18 -7,064.70
Operating Cash Flow to Interest Expense		 -24.23 -81.10 -9,564.00
Operating Cash Flow Less CapEx to Interest Expense		 -24.36 -81.45 -9,572.75
Efficiency Ratios		 - - -
Asset Turnover		 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00
Capital & Investment Metrics		 - - -
Invested Capital		 -3.90 0.58 -7.23
Invested Capital Turnover		 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 1.35 4.48 -7.81
Enterprise Value (EV)		 4.29 3.60 210
Market Capitalization		 116 86 317
Book Value per Share		 $1.79 $1.29 $1.30
Tangible Book Value per Share		 $1.79 $1.29 $1.30
Total Capital		 117 84 100
Total Debt		 9.15 1.00 0.75
Total Long-Term Debt		 2.15 1.00 0.75
Net Debt		 -111 -82 -107
Capital Expenditures (CapEx)		 0.16 0.14 0.04
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -4.29 -1.25 -8.70
Debt-free Net Working Capital (DFNWC)		 116 82 99
Net Working Capital (NWC)		 109 82 99
Net Nonoperating Expense (NNE)		 8.22 5.32 12
Net Nonoperating Obligations (NNO)		 -111 -82 -107
Total Depreciation and Amortization (D&A)		 -0.27 -1.82 -1.22
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00%
Earnings Adjustments		 - - -
Adjusted Basic Earnings per Share		 ($0.45) ($0.29) ($0.47)
Adjusted Weighted Average Basic Shares Outstanding		 64.54M 99.03M 101.97M
Adjusted Diluted Earnings per Share		 ($0.45) ($0.29) ($0.47)
Adjusted Weighted Average Diluted Shares Outstanding		 64.54M 99.03M 101.97M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 60.05M 68.96M 96.68M
Normalized Net Operating Profit after Tax (NOPAT)		 -21 -24 -36
Normalized NOPAT Margin		 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00%
Debt Service Ratios		 - - -
EBIT to Interest Expense		 -25.59 -85.56 -12,884.75
NOPAT to Interest Expense		 -18.00 -60.73 -9,016.70
EBIT Less CapEx to Interest Expense		 -25.73 -85.91 -12,893.50
NOPAT Less CapEx to Interest Expense		 -18.14 -61.08 -9,025.45
Payout Ratios		 - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -0.78% -0.89% 0.00%

Quarterly Metrics and Ratios for Trevi Therapeutics

This table displays calculated financial ratios and metrics derived from Trevi Therapeutics' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -24.78% 15.38% -15.98% -9.01% -11.78% -35.80% -53.76% -58.29% -52.25% -35.10%
EBIT Growth		 -20.90% 22.53% -5.15% -3.43% -5.78% -40.33% -60.95% -61.55% -58.56% -36.97%
NOPAT Growth		 -20.99% 19.53% -7.66% -7.19% -7.61% -34.19% -57.42% -58.54% -55.74% -37.04%
Net Income Growth		 -13.94% 35.39% 12.66% 11.26% 6.87% -42.07% -70.32% -72.88% -72.02% -45.95%
EPS Growth		 64.71% 121.74% 75.00% 50.00% 33.33% -260.00% -83.33% -71.43% -62.50% -37.50%
Operating Cash Flow Growth		 -18.44% -1.64% -15.58% -59.89% 15.12% -0.44% -27.69% 12.07% -31.28% -50.18%
Free Cash Flow Firm Growth		 3.70% -44.21% -118.81% -244.16% -183.54% -78.57% -7.80% 64.89% 81.88% 92.90%
Invested Capital Growth		 -35.73% 25.70% 80.50% 134.20% 136.59% 114.80% 151.67% -220.58% -418.35% -1,353.21%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -7.53% 19.56% -16.97% -7.76% -10.26% 2.28% -32.44% -10.93% -6.06% 13.29%
EBIT Q/Q Growth		 -5.64% 24.24% -16.17% -11.23% -8.04% -0.51% -33.25% -11.65% -6.05% 13.18%
NOPAT Q/Q Growth		 -7.48% 20.80% -13.61% -10.83% -7.91% 1.24% -33.28% -11.62% -6.01% 13.10%
Net Income Q/Q Growth		 -2.66% 33.40% -16.28% -11.62% -7.74% -1.60% -39.39% -13.30% -7.21% 13.80%
EPS Q/Q Growth		 14.29% 141.67% -220.00% -16.67% -14.29% 0.00% -37.50% -9.09% -8.33% 15.38%
Operating Cash Flow Q/Q Growth		 -38.86% 26.18% -29.47% -20.47% 26.29% 12.64% -64.60% 17.04% -10.05% 0.06%
Free Cash Flow Firm Q/Q Growth		 -14.58% -30.79% -49.67% -53.44% 5.60% 17.63% 9.65% 50.02% 51.29% 67.74%
Invested Capital Q/Q Growth		 17.08% 20.45% 77.01% 325.56% -11.28% -67.82% -19.76% -626.35% -134.22% -26.68%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 99.92% 99.64% 99.89% 99.58% 99.83% 100.23% 99.93% 99.94% 99.77% 100.15%
Interest Burden Percent		 98.43% 86.76% 86.62% 87.19% 86.73% 87.32% 91.63% 92.97% 94.15% 93.12%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -53.04% -46.82% -50.31% -35.11% -26.81% -30.59% -38.57% -48.09% -59.65% -52.59%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% -1,466.35% -1,608.81% -4,891.01% -6,078.88% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -53.04% -46.82% -50.31% -35.11% -26.81% -30.59% -38.57% -48.09% -59.65% -52.59%
Return on Equity Simple (ROE_SIMPLE)		 -29.27% 0.00% -27.74% -28.73% -29.85% 0.00% -46.40% -58.59% -75.15% 0.00%
Net Operating Profit after Tax (NOPAT)		 -5.88 -4.66 -5.29 -5.87 -6.33 -6.25 -8.33 -9.30 -9.86 -8.57
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -3.67% -1.26% -1.88% -1.60% -1.35% -1.62% -2.94% -3.77% -4.43% -3.01%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - -7.48% - - - -8.54%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -8.41 -6.37 -7.40 -8.23 -8.89 -8.94 -12 -13 -14 -12
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -8.47 -6.81 -7.97 -8.59 -9.47 -9.25 -12 -14 -14 -12
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 0.60 1.08 1.09 1.51 1.55 1.04 3.29 3.17 4.11 3.18
Price to Tangible Book Value (P/TBV)		 0.60 1.08 1.09 1.51 1.55 1.04 3.29 3.17 4.11 3.18
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 24.99 28.65 6.24 358.62 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.10 0.09 0.08 0.01 0.01 0.01 0.01 0.01 0.01 0.01
Long-Term Debt to Equity		 0.03 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01
Financial Leverage		 -1.07 -1.07 -1.05 -1.03 -1.02 -1.02 -1.00 -1.00 -1.03 -1.04
Leverage Ratio		 1.32 1.30 1.31 1.17 1.12 1.12 1.12 1.08 1.11 1.10
Compound Leverage Factor		 1.30 1.13 1.13 1.02 0.97 0.98 1.03 1.01 1.04 1.02
Debt to Total Capital		 8.95% 7.85% 7.82% 1.14% 1.16% 1.20% 1.30% 1.32% 1.36% 0.74%
Short-Term Debt to Total Capital		 5.80% 6.00% 6.78% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 3.15% 1.85% 1.04% 1.14% 1.16% 1.20% 1.30% 1.32% 1.36% 0.74%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 91.05% 92.15% 92.18% 98.86% 98.84% 98.80% 98.71% 98.68% 98.64% 99.26%
Debt to EBITDA		 -0.35 -0.30 -0.28 -0.03 -0.03 -0.03 -0.02 -0.02 -0.02 -0.01
Net Debt to EBITDA		 3.67 3.71 3.30 2.92 2.67 2.32 1.82 1.54 1.31 2.03
Long-Term Debt to EBITDA		 -0.12 -0.07 -0.04 -0.03 -0.03 -0.03 -0.02 -0.02 -0.02 -0.01
Debt to NOPAT		 -0.49 -0.44 -0.40 -0.05 -0.05 -0.04 -0.04 -0.03 -0.02 -0.02
Net Debt to NOPAT		 5.20 5.32 4.82 4.29 3.96 3.45 2.68 2.27 1.92 2.96
Long-Term Debt to NOPAT		 -0.17 -0.10 -0.05 -0.05 -0.05 -0.04 -0.04 -0.03 -0.02 -0.02
Altman Z-Score		 0.75 2.96 2.83 12.34 10.71 4.51 19.07 11.98 9.38 13.96
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 8.70 9.15 8.65 21.06 18.16 15.03 14.55 10.68 7.38 10.41
Quick Ratio		 8.58 8.99 8.43 19.99 17.18 14.25 13.80 10.29 7.18 10.24
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -4.59 -6.01 -8.99 -14 -13 -11 -9.69 -4.84 -2.36 -0.76
Operating Cash Flow to CapEx		 -19,944.19% -5,457.76% -14,380.70% -24,687.50% -40,438.89% -28,904.55% 0.00% -31,010.71% 0.00% -136,428.57%
Free Cash Flow to Firm to Interest Expense		 -15.73 -21.93 -38.93 -90.18 -4,341.50 -2,682.03 -9,693.20 -4,844.30 -2,359.90 -761.40
Operating Cash Flow to Interest Expense		 -29.37 -23.11 -35.48 -64.54 -2,426.33 -1,589.75 -10,467.00 -8,683.00 -9,556.00 -9,550.00
Operating Cash Flow Less CapEx to Interest Expense		 -29.52 -23.53 -35.73 -64.80 -2,432.33 -1,595.25 -10,467.00 -8,711.00 -9,556.00 -9,557.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 -4.90 -3.90 -0.90 2.02 1.79 0.58 0.46 -2.44 -5.71 -7.23
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -1.29 1.35 3.70 7.93 6.69 4.48 1.36 -4.46 -7.50 -7.81
Enterprise Value (EV)		 -49 4.29 8.46 51 51 3.60 166 141 178 210
Market Capitalization		 66 116 111 144 139 86 238 210 242 317
Book Value per Share		 $2.57 $1.79 $1.69 $1.58 $1.40 $1.29 $1.05 $0.94 $0.81 $1.30
Tangible Book Value per Share		 $2.57 $1.79 $1.69 $1.58 $1.40 $1.29 $1.05 $0.94 $0.81 $1.30
Total Capital		 121 117 110 96 91 84 73 67 60 100
Total Debt		 11 9.15 8.63 1.10 1.05 1.00 0.95 0.88 0.82 0.75
Total Long-Term Debt		 3.80 2.15 1.15 1.10 1.05 1.00 0.95 0.88 0.82 0.75
Net Debt		 -115 -111 -103 -93 -88 -82 -72 -69 -65 -107
Capital Expenditures (CapEx)		 0.04 0.12 0.06 0.04 0.02 0.02 0.00 0.03 0.00 0.01
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -5.93 -4.29 -2.78 0.35 -0.09 -1.25 -1.33 -4.12 -7.28 -8.70
Debt-free Net Working Capital (DFNWC)		 120 116 108 95 89 82 71 65 58 99
Net Working Capital (NWC)		 113 109 101 95 89 82 71 65 58 99
Net Nonoperating Expense (NNE)		 2.38 0.85 1.11 1.28 1.37 1.57 2.57 3.05 3.38 2.85
Net Nonoperating Obligations (NNO)		 -115 -111 -103 -93 -88 -82 -72 -69 -65 -107
Total Depreciation and Amortization (D&A)		 -0.07 -0.45 -0.57 -0.36 -0.58 -0.32 -0.35 -0.30 -0.32 -0.26
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.12) $0.05 ($0.06) ($0.07) ($0.08) ($0.08) ($0.11) ($0.12) ($0.13) ($0.11)
Adjusted Weighted Average Basic Shares Outstanding		 68.90M 64.54M 98.61M 98.70M 99.33M 99.03M 99.52M 101.04M 101.28M 101.97M
Adjusted Diluted Earnings per Share		 ($0.12) $0.05 ($0.06) ($0.07) ($0.08) ($0.08) ($0.11) ($0.12) ($0.13) ($0.11)
Adjusted Weighted Average Diluted Shares Outstanding		 68.90M 64.54M 98.61M 98.70M 99.33M 99.03M 99.52M 101.04M 101.28M 101.97M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 59.92M 60.05M 60.07M 63.85M 63.86M 68.96M 70.44M 72.59M 76.87M 96.68M
Normalized Net Operating Profit after Tax (NOPAT)		 -5.88 -4.66 -5.29 -5.87 -6.33 -6.25 -8.33 -9.30 -9.86 -8.57
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 -28.78 -23.24 -32.03 -53.78 -2,963.67 -2,234.00 -11,907.00 -13,294.00 -14,098.00 -12,240.00
NOPAT to Interest Expense		 -20.15 -17.01 -22.92 -38.35 -2,110.50 -1,563.28 -8,334.20 -9,302.30 -9,860.90 -8,569.40
EBIT Less CapEx to Interest Expense		 -28.93 -23.66 -32.27 -54.05 -2,969.67 -2,239.50 -11,907.00 -13,322.00 -14,098.00 -12,247.00
NOPAT Less CapEx to Interest Expense		 -20.30 -17.43 -23.16 -38.61 -2,116.50 -1,568.78 -8,334.20 -9,330.30 -9,860.90 -8,576.40
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -0.49% -0.78% -0.70% -0.81% -0.86% -0.89% -0.72% -0.59% -0.13% 0.00%

Frequently Asked Questions About Trevi Therapeutics' Financials

When does Trevi Therapeutics's fiscal year end?

According to the most recent income statement we have on file, Trevi Therapeutics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Trevi Therapeutics' net income changed over the last 2 years?

Trevi Therapeutics' net income appears to be on an upward trend, with a most recent value of -$47.91 million in 2024, rising from -$29.15 million in 2022. The previous period was -$29.07 million in 2023.

What is Trevi Therapeutics's operating income?
Trevi Therapeutics's total operating income in 2024 was -$51.52 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $51.52 million
How has Trevi Therapeutics revenue changed over the last 2 years?

Over the last 2 years, Trevi Therapeutics' total revenue changed from $0.00 in 2022 to $0.00 in 2024, a change of 0.0%.

How much debt does Trevi Therapeutics have?

Trevi Therapeutics' total liabilities were at $11.26 million at the end of 2024, a 64.2% increase from 2023, and a 27.6% decrease since 2022.

How much cash does Trevi Therapeutics have?

In the past 2 years, Trevi Therapeutics' cash and equivalents has ranged from $12.59 million in 2022 to $34.10 million in 2024, and is currently $34.10 million as of their latest financial filing in 2024.

How has Trevi Therapeutics' book value per share changed over the last 2 years?

Over the last 2 years, Trevi Therapeutics' book value per share changed from 1.79 in 2022 to 1.30 in 2024, a change of -27.7%.

Remove Ads

Related Companies

This page (NASDAQ:TRVI) was last updated on 4/16/2025 by MarketBeat.com Staff
From Our Partners
Why Elon put $51 million into this
Why Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT Scientists
True Market Insiders | Sponsored
Trump Makes Major Crypto Announcement
Trump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...
Crypto 101 Media | Sponsored
Warning: “DOGE Collapse” imminent
Elon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...
Altimetry | Sponsored
Crypto’s crashing…but we’re still profiting
Most traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....
Crypto Swap Profits | Sponsored
Now I look stupid. Real stupid...
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...
Porter & Company | Sponsored
Is it CRAZY to still want reliable profits, despite this market?
Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...
Brownstone Research | Sponsored
REVEALED FREE: Our top 3 stocks to own in 2025 and beyond
Every time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...
Weiss Ratings | Sponsored
First look: The $3,500 iPhone
Did you hear that just before Trump's tariffs took effect, Apple sent five cargo planes packed with MacBooks a...
Stansberry Research | Sponsored